Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro-DexFRA:PDXN +1.90%71 OCF Margin % is -1.34% as of Jun. 2026. GuruFocus rates FRA:PDXN with a GF Score™ of 71/100 and a GF Value™ of €35.38 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Pro-Dex ranks better than 58.55% on this metric.
The historical rank and industry rank for Pro-Dex's OCF Margin % or its related term are showing as below:
FRA:PDXN'
s OCF Margin % Range Over the Past 10 Years
Min: -5.46 Med: 11.71 Max: 14.74
Current: 9.29
During the past 13 years, the highest OCF Margin % of Pro-Dex was 14.74%. The lowest was -5.46%. And the median was 11.71%.
FRA:PDXN's OCF Margin % is ranked better than 58.55% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: 6.64
vs FRA:PDXN: 9.29
The historical data trend for Pro-Dex's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PDXN vs ZJYL, UTMD, OSUR: OCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Pro-Dex's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro-Dex OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pro-Dex's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Pro-Dex's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro-Dex (FRA:PDXN) has a OCF Margin % of -1.34% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pro-Dex and its competitors. According to the industry distribution chart, Pro-Dex ranks #337 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 41.5%.
Is Pro-Dex's OCF Margin % too high?
Pro-Dex's current OCF Margin % is -1.34%. Based on the distribution chart, Pro-Dex ranks #337 out of 813 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pro-Dex has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pro-Dex's OCF Margin % compare to ZJYL and UTMD?
According to the Medical Devices & Instruments industry distribution chart, Pro-Dex ranks #337 out of 813 companies for OCF Margin %. This puts Pro-Dex in the upper half of its industry. The industry median OCF Margin % is 6.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 6.64, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pro-Dex and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 6.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro-Dex's current OCF Margin % is -1.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro-Dex stock overvalued right now?
Based on GuruFocus' analysis, Pro-Dex (FRA:PDXN) is currently considered Significantly Overvalued. The stock's GF Value™ is €35.38, compared to a current price of €53.50 — trading 51.2% above its estimated fair value. The current OCF Margin % is -1.34%. Pro-Dex's overall GF Score™ is 71/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Pro-Dex (FRA:PDXN), the current OCF Margin % is -1.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro-Dex (FRA:PDXN) Overvalued in 2026?
Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued.
The current stock price of €53.50 is trading 51.2% above its estimated GF Value™ of €35.38.
GuruFocus considers Pro-Dex to be Significantly Overvalued.
Key valuation signals for FRA:PDXN:
OCF Margin %: -1.34%
GF Value™: €35.38 vs. price of €53.50 (51.2% above fair value)
No single metric tells the full story. See the FRA:PDXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
71GF Score
Get the complete analysis for FRA:PDXN
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDXN has been successfully added to your 
